A case of post-BCG therapy renal granuloma concurrent with ureteral carcinoma

Tatsuya Otaki; Nobuyuki Nakajima; Akira Miyajima

doi:10.1016/j.eucr.2023.102379

A case of post-BCG therapy renal granuloma concurrent with ureteral carcinoma

Urol Case Rep. 2023 Mar 7:47:102379. doi: 10.1016/j.eucr.2023.102379. eCollection 2023 Mar.

Authors

Tatsuya Otaki¹, Nobuyuki Nakajima¹, Akira Miyajima²

Affiliations

¹ Department of Urology, Tokai University Oiso Hospital, Japan.
² Department of Urology, Tokai University School of Medicine, Japan.

Abstract

Intravesical administration of Bacillus Calmette-Guerin (BCG) is recommended to reduce the risk of recurrence or progression of carcinoma in situ, stage Ta tumors of high grade, or stage T1 tumors. Renal complications following intravesical BCG therapy are rare. The mechanism of renal granuloma formation may be related to vesicoureteral reflux. Vesicoureteral reflux after transurethral resection of bladder tumors (TURBT) has been reported to be higher when the tumor is located near the ureteral orifice. Herein, we report a case of a renal granuloma after BCG therapy with concurrent ipsilateral urethral carcinoma.

Keywords: Bacillus calmette-guerin; Bladder cancer; Renal granuloma.

Publication types

Case Reports